Enzon Inc. deal

ENZN entered into a non-exclusive license with the National Institutes of Health for cancer detection agents based on NIH-developed monoclonal antibodies. ENZN will develop Single-Chain Antigen-Binding proteins based on the MAbs. The company said the MAb furthest in development, CC49, may have application for the detection of breast, lung and colorectal cancers. ...